Kommentar zu Kastrationsresistentes Prostatakarzinom: [177Lu]Lu-PSMA-617 versus Cabazitaxel

Aktuelle Urol 2023; 54(04): 269-270
DOI: 10.1055/a-2084-8214

Referiert und kommentiert

Kommentar zu Kastrationsresistentes Prostatakarzinom: [¹⁷⁷Lu]Lu-PSMA-617 versus Cabazitaxel

Tilman Todenhöfer

¹Studienpraxis Urology, Nürtingen, Deutschland

²Medical School, Universität Tübingen, Tübingen, Deutschland

Literatur
1 Hofman MS, Emmett L, Sandhu S. et al. [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 2021; 397: 797-804
2 Hofman MS, Emmett L, Sandhu S. et al. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel – Overall survival after median follow-up of 3 years (ANZUP 1603). Journal of Clinical Oncology 2022; 40 (Suppl. 16) 5000-5000
3 Buteau JP, Martin AJ, Emmett L. et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol 2022; 23: 1389-1397
4 Kuo P, Hesterman J, Rahbar K. et al. [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy. Journal of Clinical Oncology 2022; 40 (Suppl. 16) 5002-5002